MC2 Plots Course For Topical Psoriasis Drug Launch After Positive Phase III Data
Executive Summary
The Danish company is planning to file an NDA with the US FDA in 2019 after reporting positive Phase III data showing the topical cream MC2-01 was superior to Leo Pharma's Taclonex.
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.